29 results about "Folate receptor" patented technology

A conjugate comprising a ligand that targets a folate receptor linked to an acrolein scavenger drug; a composition comprising same; a method of using the conjugate or the composition to scavenge acrolein, alone or in further combination with other reactive aldehyde species, in a subject with neurotrauma; and a method of delivering an acrolein scavenger or an imaging agent to the central nervous system (CNS) of a patient with inflammation in the CNS.

The invention discloses a near-infrared fluorescence imaging agent of a targeted folate receptor, an imaging system and application of the imaging agent and the imaging system, and belongs to the technical field of biomedical treatment. The technical problem to be solved is to provide the folate receptor-targeted near-infrared fluorescence imaging system, an imaging agent in the system can specifically target the folate receptor FR-alpha, and the folate receptor-targeted near-infrared fluorescence imaging system is used in application scenes of lung cancer and ovarian cancer and can show higher TNR, display tumor boundaries in real time and reduce the positive edge cutting rate. According to the technical scheme, the near-infrared fluorescence imaging agent of the targeted folic acid receptor is characterized by comprising a compound of the targeted folic acid receptor, a solvent and pharmaceutically acceptable auxiliary materials, the structure of the compound of the targeted folic acid receptor is F-L-D, F is the structure of the targeted folic acid receptor, D is a near-infrared dye, L is a connexon, and L is an electron donor. The structural formula is shown in the specification or pharmaceutically acceptable salts thereof.

The invention discloses a complement amplification folic acid optical fiber sensing system and a folic acid concentration detection method thereof. The sensing system comprises an excitation light source, an optical fiber sensing probe, a micro-fluidic plate, a nanogold rod amplification solution and a spectrograph, the excitation light source, the optical fiber sensing probe and the spectrograph are sequentially communicated, the optical fiber sensing probe is introduced into the micro-fluidic plate, the nanogold rod amplification solution is introduced into the micro-fluidic plate, and the nanogold rod amplification solution is introduced into the spectrograph. The optical fiber sensing probe is a folic acid receptor protein modified gold-plated film optical fiber, and the nanogold rod amplification solution is a folic acid modified nanogold rod solution. Under the participation of the gold nanoparticles, the optical fiber sensing probe realizes enhanced plasma resonance wavelength shift, so that the sensitivity of folic acid molecule detection is remarkably improved, folic acid in a solution can be quickly and directly measured, and the application range is wide.

Disclosed in the present invention are a fluorescent molecule targeting a folate receptor, a preparation method therefor and the use thereof. The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a tautomer thereof. The compound of the present invention can be used as a fluorescent contrast agent in near-infrared surgical navigation.

The invention provides a dual-targeting nano-material photosensitizer for cervical cancer as well as a preparation method and application of the dual-targeting nano-material photosensitizer. The folic acid modified poly-beta-cyclodextrin (poly-beta-CD) is used as a nano-carrier and is used for loading a photosensitizer PAP (PAP is pyropheophorbide a covalently connected PAAKRVKLD) coupled with a nuclear localization signal (NLSs). The finally prepared FA-CD-coated PAP nano material can specifically recognize cervical cancer cells of overexpressed folate receptors (FR), so that accumulation in tumor cells is remarkably enhanced. In addition, the encapsulated PAP can achieve accurate cell nucleus localization. Under an illumination condition, reactive oxygen species (ROS) generated by PAP accumulated in nuclei can instantly oxidize and damage a DNA chain or DNA repair enzyme, so that cell death is directly induced, and the anti-tumor effect of targeted photodynamic is greatly enhanced. The novel dual-targeting nano drug-loading system prepared by the invention solves the problems of poor targeting and biological solubility and limited treatment effect of a traditional photosensitizer, and provides an innovative intelligent targeting delivery strategy for in-situ cell nucleus photodynamic therapy.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The invention discloses a compound and a composition of a targeted folate receptor as well as a preparation method and application of the compound and the composition, and belongs to the technical field of medical biology, the compound of the targeted folate receptor is F-L-D, F is a structure of the targeted folate receptor, D is a near-infrared dye, L is a connexon, and the structural formula is shown in the specification or a pharmaceutically acceptable salt thereof. The compound of the targeted folate receptor is used as a targeted near-infrared fluorescence imaging agent, can be matched with a near-infrared fluorescence imaging system for use, can specifically target the folate receptor FR-alpha, and is used for auxiliary diagnosis of identifying malignant lesions in a tumor patient operation. In application scenarios of lung cancer and ovarian cancer, the compound can show higher TNR and can display tumor boundaries in real time so as to help to identify intraoperative lesions, reduce the positive edge cutting rate and the false positive rate and realize accurate excision.

The application belongs to the field of biological medicine, and provides a tumor microenvironment responsive nano-drug, which comprises a ferrous metal organic framework, polyethylene glycol / leafy on the modified ferrous metal organic framework and PK11195 encapsulated in the metal framework, and a structural formula of the PK11195 is as shown below. The application also provides a preparation method of the tumor microenvironment responsive nano-drug. The application also provides the use of the tumor microenvironment responsive nano-drug in the preparation of a drug for treating hepatocellular carcinoma. The nano-drug can be actively targeted to tumor cells by combining with folate receptors, under the guidance of MRI, and rich ROS is generated by the irradiation of near-infrared light, so as to induce cell ICD, which provides a prospect for promoting systemic antitumor photodynamic therapy and immunotherapy.

The invention discloses an anti-cervical cancer nano targeting tablet based on a traditional Chinese medicine compound and a preparation method thereof. The nano targeting tablet is prepared from the following raw materials in parts by weight: centipede, bungarus parvus, syngnathus, scorpio, nidus vespae, leech, ground beeltle, frankincense, myrrh, dandelion, rhizoma cyperi, radix bupleuri, fructus aurantii, cortex phellodendri, angelica sinensis, radix curcumae, poria cocos, bighead atractylodes rhizome, radix paeoniae alba, cortex albiziae, Chinese yam, oldenlandia diffusa and selfheal. According to the invention, active ingredients of the traditional Chinese medicinal materials are retained and enriched to the maximum extent through a modern extraction technology, the curative effect of the original formula is ensured to be retained to the maximum extent, and through a folic acid receptor, CD44 receptor and pH sensitive triple targeting mechanism, the medicine is enriched in cervical cancer tissues, the local medicine concentration is improved, the system toxicity is reduced, and accurate targeting delivery is realized.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The application discloses a kind of lysosome-targeting protein modulators based on upconversion nanomaterial-DNA nanostructure and preparation method thereof.The lysosome-targeting protein modulators are combined by covalent bond from carboxyl functionalized upconversion nanoparticles and amino-modified DNA nanostructure, mainly enter cancer cells through folate receptor, after near infrared light illumination and glutathione response, the target protein combined is transported into lysosome and degraded.The lysosome-targeting protein modulators of the application have the advantages of light affinity, high controllability and storage stability, are easy to be metabolized by organism, and have good application prospect in the field of cell biology and cancer targeted therapy.

Photodynamic therapy (PDT) is a minimally invasive treatment that involves the administration of a light-activatable drug followed by light activation of the lesion to produce reactive oxygen species that kill cancer cells. VISUDYNE®, a liposomal formulation of benzoporphyrin derivative (BPD) photosensitizer, is clinically approved for PDT of ocular diseases and is now being tested for PDT and imaging of pancreatic, brain, and other cancers. While VISUDYNE® improves the pharmacokinetics of BPD, it lacks treatment selectivity. This present disclosure is directed to dBPD, dBPD nanoparticles, and preparation and use thereof that provide cancer treatment selectivity for cancers characterized by overexpression of folate receptor (FR).

The invention belongs to the field of functional nano-materials, and particularly relates to a silicon-based mesoporous nano-drug delivery system with folic acid modified on the surface and a preparation method and application thereof. The preparation method comprises the steps of mesoporous silicon synthesis, amino modification, folic acid grafting, drug impregnation and the like, and further comprises preferable schemes such as metal doping (Fe, Cu) and the like. The drug delivery system significantly improves the stability and bioavailability of a part of insoluble drugs. Meanwhile, aiming at the microenvironment characteristics that tumor tissues are acidic and rich in folic acid receptors, the drug delivery system realizes dual functions of pH responsiveness and initiative through folic acid modification, so that the damage to normal tissues is effectively reduced, and accurate delivery and controllable release of drugs at tumor parts are realized. According to the technical scheme, a new solution is provided for clinical application of indissolvable drugs, and the pharmaceutical composition can be used for treating various diseases.

The invention discloses a folic acid modified NK cell-derived exosome entrapped oncolytic reovirus compound as well as a preparation method and an application of the folic acid modified NK cell-derived exosome entrapped oncolytic reovirus compound. In the compound, folic acid and an NKexo phospholipid bilayer modify NKexo in a self-assembly insertion manner; in the compound, Reo is loaded into NKexo through an extrusion method. The method comprises the following steps: extracting NKexo, modifying the NKexo by folic acid, and entrapping Reo by the folic acid modified NKexo. The folic acid modified NKexo entrapped Reo disclosed by the invention not only can become a better conveying carrier by virtue of the anti-tumor characteristic of NKexo, but also can be combined with a folic acid receptor which is highly expressed in a tumor through folic acid, so that more Reo is protected and delivered to a tumor part, and the cancer is synergistically and jointly treated in a targeted manner.

This invention discloses a fluorescent molecule targeting the folic acid receptor, its preparation method, and its applications. This invention provides a compound as shown in formula (I), its pharmaceutically acceptable salt, or its tautomer. The compound of this invention can be used as a fluorescent contrast agent in near-infrared surgical navigation.

The present invention provides a small molecule compound targeting a folate receptor, a preparation method, a composition, and a use. Specifically provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof provided by the present invention can be used as a small molecule targeted fluorescent contrast agent for adjuvant surgical treatment, and has a novel structure and good targeting performance. A near infrared fluorescence capture system provided by the present invention facilitates tumor diagnosis and treatment and has good application prospects.

The invention provides application of a targeted folate receptor antibody coupling medicine in colorectal cancer and humanization of the targeted folate receptor antibody coupling medicine. Specifically, the invention provides an application of a drug conjugate formed by coupling an anti-FOLR1 antibody and VcMMAE in treatment of colorectal cancer. In addition, the invention also provides application of the combined combination of the drug conjugate and gemcitabine in colorectal cancer treatment, and compared with independent administration, the combined combination of the drug conjugate and gemcitabine has a better inhibition effect on colorectal cancer.

The invention relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of a primary hepatocellular carcinoma target-free drug and application of the combined marker, and the combined marker is a folate receptor gamma gene FOLR3 derived from peripheral blood leucocyte mRNA, a layered protein gene SFN and a coiled-coil domain protein 9 gene CCDC9. According to the invention, combined detection is carried out based on a plurality of peripheral blood leucocyte markers, and compared with a single molecular marker, errors caused by individual expression difference of a single index can be reduced to a certain extent, so that the detection result is more accurate. The curative effect prediction model constructed based on detection of peripheral blood leucocyte mRNA level change can perform specific recognition detection in the initial stage of tumor formation, has high sensitivity and high specificity, and provides an important means for reasonable medication of hepatocellular carcinoma patients sensitive or resistant to target-free drugs. The important significance is realized on the effective treatment of the hepatocellular carcinoma in China.

The invention discloses a superparamagnetic nano drug delivery system with biological and magnetic dual targeting and tumor drug and magnetic and thermal dual tumor cell killing and application, and belongs to the technical field of biological medicine. The system is composed of a lipid component, a chemotherapeutic drug and surface carboxyl modified FeO nanoparticles, wherein the lipid component is prepared from cholesterol, DSPE-PEG2000 and folic acid modified DSPE-PEG2000. According to the drug loading system, efficient enrichment of tumor sites is achieved through folic acid receptor mediated biological targeting and physical targeting of an external magnetic field, and tumor cells are killed through chemotherapy drugs and a magnetocaloric effect in a synergistic mode. Experiments show that the encapsulation efficiency of the system on adriamycin reaches 80%, the drug release rate under the magnetocaloric condition is 50%-60%, and the system shows significant targeting and killing effects in tumor cells expressing folate receptors. The invention has the advantages of simple preparation process, strong targeting property, high killing efficiency, low toxic and side effects and the like, and is suitable for thermochemotherapy treatment of cancers.

A bispecific antibody is described comprising a first antigen binding arm that binds FRa receptor and a second antigen-binding arm that binds CD3, wherein: a) the first antigen-binding arm (A) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), A- VHCDR1, A-VHCDR2 and A- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 1, 2 and 3 respectively three light chain complementarity determining regions (CDRs), A- VLCDR1, A-VLCDR2 and A- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 4, 5 and 6 respectively b) the second antigen-binding arm (B) of the bispecific antibody comprises: three heavy chain complementarity determining regions (CDRs), B- VHCDR1, B-VHCDR2 and B- VHCDR3 comprising the aminoacid sequences of SEQ ID NO: 7, 8 and 9 respectively three light chain complementarity determining regions (CDRs), B- VLCDR1, B-VLCDR2 and B- VLCDR3 comprising the aminoacid sequences of SEQ ID NO: 10, 11 and 12 respectively. Furthermore, the pharmaceutical composition comprising said bispecific antibody and its pharmaceutical use are described.

The application belongs to the technical field of medicines, and particularly relates to a medicine preparation for reversing cisplatin drug resistance of ovarian cancer and a preparation method thereof; wherein the medicine preparation for reversing cisplatin drug resistance of ovarian cancer comprises the following raw materials in parts by weight: 5-15 parts of cisplatin and 80-100 parts of a lipid film; the synergistic effect of upstream and downstream pathway blockage formed by the SPHK1 inhibitor and the S1PR1 antagonist is combined with cisplatin, which directly enhances the killing of the chemotherapy drug on the drug-resistant cells, reduces the drug resistance by improving the tumor immune microenvironment through reducing the immunosuppressive macrophages, and realizes more efficient reversal of cisplatin drug resistance. A double-targeted delivery system is constructed in the lipid film: folate can specifically recognize the folate receptor highly expressed by the ovarian cancer cells, and mannose targets the mannose receptor on the surface of the M2 type macrophages, so that the drug is double-enriched in the tumor cells and the tumor microenvironment.

The present application provides a kind of targeting folate receptor antibody conjugated drug in colorectal cancer and its humanization.The specific application provides the application of the drug conjugate of anti-FOLR1 antibody and VcMMAE conjugation in the treatment of colorectal cancer.In addition, the present application also provides the application of the combination of the drug conjugate and gemcitabine in the treatment of colorectal cancer, and the combination of the drug conjugate and gemcitabine has better inhibitory effect on colorectal cancer than single administration.

The application provides a folate / lactobionic acid dual-ligand modified chitosan nanoliposome as well as a preparation method and application thereof, and belongs to the field of biomaterials. The chitosan nanoliposome is obtained by incubating folate modified galactosylated chitosan with liposomes. The nanoliposome utilizes ASGPR and folate receptors to realize liver targeting. The nanoliposome is used to deliver gimatecan, so as to solve the problems of poor bioavailability and low solubility of gimatecan. Meanwhile, it is found that the combination of GER@GC-LIP and folate can play a synergistic anti-tumor effect. The application provides a potential drug preparation for hepatocellular carcinoma treatment, and has a good application prospect.

The application discloses a kind of compound, composition, its preparation method and application of targeting folate receptor, belong to medical biotechnology field, the compound of targeting folate receptor is F-L-D, wherein, F is the structure of targeting folate receptor, D is near infrared dye, L is linker, structural formula is: Or its pharmaceutically acceptable salt.The compound of targeting folate receptor of the application is used as targeted near infrared fluorescent imaging agent, can be used with near infrared fluorescent camera system, can specifically target folate receptor FR-alpha, is used for the auxiliary diagnosis of intraoperative identification of malignant lesion of tumor patient.The application scene of the compound in lung cancer, ovarian cancer, can show higher TNR, can show tumor boundary in real time, to help identify intraoperative lesion, reduce positive margin rate and false positive rate, realize accurate resection.

The invention relates to a targeted delivery carrier as well as a preparation method and application thereof. The delivery carrier comprises EVs of which the surfaces are modified with FA. Through specific binding of surface FA and a folate receptor highly expressed by TNBC cells, precise targeting of TNBC is realized, the core problem of poor targeting performance of traditional vectors such as EVs and lipidosome is effectively solved, and a foundation is laid for efficient delivery of genes to tumor sites. The drug prepared from the delivery carrier can deliver METTL3 cDNA to TNBC cells in a targeted manner, low-expression METTL3 in TNBC can be remarkably recovered, and degradation of tumor-related gene RPL19 mRNA is further accelerated through METTL3-mediated m6A modification, so that the dual treatment effects of targeted regulation and control of a molecular mechanism and efficient tumor inhibition are finally achieved.

The application relates to the technical field of biological medicines, in particular to a folate-targeted black phosphorus quantum dot nanocomposite as well as a preparation method and application thereof. The nanocomposite comprises black phosphorus quantum dots, the surface of the black phosphorus quantum dots is grafted with folate-modified polyethylene glycol amino derivatives, and the black phosphorus quantum dots are loaded with tirapazamine. The folate is used for targeting tumor cells with high expression of folate receptors. The preparation method comprises the following steps: black phosphorus raw materials are subjected to ice bath ultrasonic peeling and centrifugation in an organic solvent to obtain black phosphorus quantum dots; the black phosphorus quantum dots are reacted with folate-modified polyethylene glycol amino derivatives to obtain folate-modified polyethylene glycol grafted black phosphorus quantum dots; and then the folate-modified polyethylene glycol grafted black phosphorus quantum dots are incubated with tirapazamine for loading and centrifugation. The nanocomposite has good dispersion stability and active targeting capability, can exert photodynamic and photothermal effects under laser irradiation, and can promote the hypoxic activation of tirapazamine, realizes synergistic effect, and can be used for preparing a tumor treatment.

This invention relates to the field of nutritional intervention technology, and more particularly to a double Pickering emulsion for targeted delivery of polyunsaturated fatty acids, its preparation method, and its application. The invention first prepares folic acid-modified soy protein isolate-chitosan electrostatic composite particles as solid particle emulsifiers to stably deliver polyunsaturated fatty acids in a double Pickering emulsion. The folic acid-modified soy protein isolate-chitosan electrostatic composite particles utilize the amphiphilic nature of soy protein isolate and the steric hindrance effect of chitosan to construct a dense, three-dimensional rigid physical barrier at the oil-water interface, significantly reducing the oxidative degradation rate of polyunsaturated fatty acids, ensuring their storage stability, and achieving long-term stability. Simultaneously, by leveraging the active targeting mediated by folic acid receptors and the pH-responsive properties of chitosan, targeted and precise controlled release and delivery of polyunsaturated fatty acids in the colon are achieved, providing a solid technical foundation for precise nutritional intervention in colon cancer.

A conjugate of formula (I) FRTL-BBMecL-AA or (II) FRTL-Alb-BBMecL-AA, wherein FRTL is a folate receptor-targeting ligand, BBMecL is a brush border membrane (BBM) enzyme-cleavable linker, Alb is an albumin-binder moiety, and AA is an active agent; composition comprising same; and method of imaging and / or treating a tumor.

This invention relates to folic acid conjugates, their preparation methods, and applications. Specifically, this invention discloses a novel folic acid conjugate and its combination therapy strategy, and also provides a method for preparing the conjugate and its application in tumor treatment. The conjugate of this invention exhibits folic acid receptor expression dependence, can effectively inhibit the proliferation of ovarian cancer cells, and shows good efficacy when used in combination with DNA damaging agents.